ICI 154,129δ selective peptide antagonist CAS# 83420-94-4 |
- KY 02111
Catalog No.:BCC3628
CAS No.:1118807-13-8
- IWR-1-endo
Catalog No.:BCC5102
CAS No.:1127442-82-3
- CCT 031374 hydrobromide
Catalog No.:BCC6258
CAS No.:1219184-91-4
- XAV-939
Catalog No.:BCC1120
CAS No.:284028-89-3
- iCRT 14
Catalog No.:BCC5401
CAS No.:677331-12-3
- IWP-2
Catalog No.:BCC1665
CAS No.:686770-61-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 83420-94-4 | SDF | Download SDF |
| PubChem ID | 3035055 | Appearance | Powder |
| Formula | C34H46N4O6S | M.Wt | 638.83 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 1 mg/ml in methanol | ||
| Sequence | YGFL (Modifications: Tyr-1 = N,N-diallyl-Tyr, Gly-2 - Phe-3 peptide bond replaced with Psi-(CH2S)) | ||
| Chemical Name | (2S)-2-[[(2S)-2-[2-[[2-[[(2S)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]ethylsulfanyl]-3-phenylpropanoyl]amino]-4-methylpentanoic acid | ||
| SMILES | CC(C)CC(C(=O)O)NC(=O)C(CC1=CC=CC=C1)SCCNC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)N(CC=C)CC=C | ||
| Standard InChIKey | CZRZYRKTYLLLRL-DTXPUJKBSA-N | ||
| Standard InChI | InChI=1S/C34H46N4O6S/c1-5-17-38(18-6-2)29(21-26-12-14-27(39)15-13-26)32(41)36-23-31(40)35-16-19-45-30(22-25-10-8-7-9-11-25)33(42)37-28(34(43)44)20-24(3)4/h5-15,24,28-30,39H,1-2,16-23H2,3-4H3,(H,35,40)(H,36,41)(H,37,42)(H,43,44)/t28-,29-,30-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Selective δ opioid antagonist. |
ICI 154,129 Dilution Calculator
ICI 154,129 Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Phenformin HCl
Catalog No.:BCC4362
CAS No.:834-28-6
- PL 017
Catalog No.:BCC5864
CAS No.:83397-56-2
- Prenyl caffeate
Catalog No.:BCC8351
CAS No.:100884-13-7
- D609
Catalog No.:BCC1509
CAS No.:83373-60-8
- 25(R)-Hydroxyprotopanaxadiol
Catalog No.:BCN2493
CAS No.:83349-37-5
- 10-O-Caffeoyl-6-epiferetoside
Catalog No.:BCN4822
CAS No.:83348-22-5
- Dynorphin B
Catalog No.:BCC5987
CAS No.:83335-41-5
- (-)-Lariciresinol
Catalog No.:BCN3418
CAS No.:83327-19-9
- 8(17),13-Labdadien-15,16-olide
Catalog No.:BCN4374
CAS No.:83324-51-0
- Bryostatin 1
Catalog No.:BCC7343
CAS No.:83314-01-6
- 7-Hydroxycoumarin-6-carboxylic acid
Catalog No.:BCN4375
CAS No.:833-52-3
- Menisporphine
Catalog No.:BCN7902
CAS No.:83287-02-9
- Boc-D-Prolinol
Catalog No.:BCC2707
CAS No.:83435-58-9
- Ebracteolata cpd B
Catalog No.:BCN3781
CAS No.:83459-37-4
- Ginsenoside Ra1
Catalog No.:BCN8392
CAS No.:83459-41-0
- Mifamurtide
Catalog No.:BCC5241
CAS No.:83461-56-7
- Voglibose
Catalog No.:BCC4750
CAS No.:83480-29-9
- Ginsenoside Rd2
Catalog No.:BCN8279
CAS No.:83480-64-2
- Grantaline
Catalog No.:BCN2083
CAS No.:83482-61-5
- 4-[4-(3-Hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-d]pyrazol-5-yl]benzoic acid
Catalog No.:BCC6341
CAS No.:834903-43-4
- Leucosceptoside A
Catalog No.:BCN7457
CAS No.:83529-62-8
- Anisofolin A
Catalog No.:BCN4377
CAS No.:83529-71-9
- 2,2-Bis(3-amino-4-hydroxyphenyl)hexafluoropropane
Catalog No.:BCC8490
CAS No.:83558-87-6
- Regorafenib hydrochloride
Catalog No.:BCC1883
CAS No.:835621-07-3
Ethological analyses of the effects of naloxone and the opiate antagonist ICI 154, 129 on social interactions in male house mice.[Pubmed:24897570]
Behav Processes. 1985 May;10(4):341-54.
The influences of the mu blocker naloxone and the novel opioid delta receptor antagonist ICI, 154, 129 on videotaped encounters between individually-housed, male Swiss mice and anosmic male 'standard opponents' were assessed using a variety of ethological analyses. The effects of drugs were studied on individual elements and on the times allocated by subjects to broad categories of behaviour. Neither of the drugs significantly altered times allocated to broad categories of behaviour. Both doses of both compounds significantly increased the incidences of some 'fearful'/defensive postures. A more detailed analysis considered the effects of the drugs on the sequences of postures used in the resident's behaviour. This involved the generation of 'dendrograms' which provided support for the view that both naloxone and ICI 154, 129 altered the associations between behavioural elements seen in saline controls (especially at higher doses) and that the effects of these antagonists were qualitatively different.
Effects of intraventricular injection of delta receptor antagonist ICI 154, 129 on the secretion of luteinizing hormone and prolactin in the proestrous rat.[Pubmed:1661235]
Endocrinol Jpn. 1991 Apr;38(2):213-8.
In order to ascertain the role of delta receptors in the control of gonadotropin secretion, a preferential delta receptor antagonist ICI 143,129 was microinjected into the third ventricle through chronically implanted cannulae and the effects on the serum concentration of luteinizing hormone (LH) and prolactin (PRL) were determined in female rats in proestrus. When the injection was given at 1030 h, ICI 154,129 (50 micrograms) exerted no significant effects on either LH or PRL. However, in the rat given a microinjection of ICI 154,129 at 1300 h, an afternoon rise in LH occurred in advance and was of greater magnitude, with the peak time more than 1 h earlier and the peak amplitude approximately 100% greater than that in the control rat, respectively. The injection also suppressed the PRL rise during the plateau phase. The results indicate that delta receptors are involved in the mediation of the inhibitory influence of endogenous opioids on the surge of LH in proestrus, and that delta receptors mediate the facilitatory influence of opioids on the PRL surge during the plateau phase.
Comparison of the influence of the opiate delta receptor antagonist, ICI 154,129, and naloxone on social interaction and behaviour in an open field.[Pubmed:6325983]
Neuropharmacology. 1984 Jan;23(1):13-7.
The influence of a novel opiate delta receptor antagonist, ICI 154,129, and naloxone on social interaction and on behaviour in an open field were compared. At a dose thought to optimally block the delta receptor, ICI 154,129 produced open field behaviour typical of a non-emotional animal: this drug decreased social investigation and the latency to attack. In contrast, naloxone was largely without effect in these tests.
ICI 154,129, a delta-opioid receptor antagonist raises seizure threshold in rats.[Pubmed:6321207]
Eur J Pharmacol. 1984 Jan 13;97(1-2):141-4.
Acute i.c.v. administration of ICI 154,129 (100-600 micrograms), a delta-opioid receptor antagonist, raised the seizure threshold in a dose-related manner in rats exposed to flurothyl, a volatile convulsant. Pretreatment with naloxone or beta-funaltrexamine (beta-FNA) antagonized this effect. Lower doses of ICI 154,129 (12.5-50 micrograms), which did not influence seizure threshold, selectively antagonized the anticonvulsant action of [D-Ala2,D-Leu5]enkephalin (DADLE) in the same procedure. Consequently, it may be inferred that ICI 154,129 at high doses has mu-agonist and at low doses delta-antagonist properties in the rat flurothyl test.
